Waterdrop Fell While Sales Rose
If you had skimmed past Waterdrop at the start of 2026, the missed opportunity would not have felt like much of a decision. Holding Waterdrop from the start of the year would have meant a 45.3% loss, including dividends. That result sits awkwardly beside earlier analyst debates about AI-driven insurance growth versus tightening regulation and demographic strain. So what specific warning sign or optimistic assumption, already on record, could you have interrogated before that slide unfolded?
The move put Waterdrop in the middle of this trade. Scan 33 healthcare AI stocks for other companies exposed to it.
The Two Waterdrop Stories Investors Were Weighing
The shares cost US$1.9 at the start of the period, and anyone looking at Waterdrop then had to choose between two very different stories that both sounded reasonable.
On the upbeat side, the bullish view put Fair Value at US$2.36. This price was implied by its own assumptions, built on rapid AI deployment lifting productivity and margins while smartphone adoption in China expanded the addressable pool for digital insurance and health services.
The cautious camp saw Fair Value nearer US$1.36, again only if its scenario played out. This view focused on tightening data and AI regulation raising compliance costs and limiting how far Waterdrop could push personalised products and long term profitability.
What The Results Changed For The Waterdrop Debate
Waterdrop’s 2025 ESG report, including the launch of its KEYI.AI underwriting tool, backed the bullish claim that heavier AI use could lift efficiency. The reported figures told a tougher story. Total revenue reached CNY 1,448.219m in Q2 2026 versus CNY 837.959m a year earlier, while net income slipped to CNY 125.772m and net margin fell from 16.7% to 8.7%. The evidence cut both ways.
The lesson is simple. When an AI-led margin story is central, track revenue, absolute profit and the reported net margin together. Then check whether efficiency projects like KEYI.AI show up as stable or improving profitability before accepting the thesis at another business.
What You Would Be Paying For In Waterdrop Today
Today Waterdrop trades at US$1, after a share price that has fallen 45.3% from the start of the year. The selected Narrative places Fair Value above that level and ties the gap to how effectively AI tools and healthcare services translate into durable earnings and cash generation.
The key assumption a buyer must weigh is that heavier AI, sales and marketing, and R&D spending will create a larger, sustainably profitable insurance and healthcare customer base instead of entrenched margin pressure.
"The current valuation implies the market is not fully pricing in Waterdrop's AI-native transformation, health insurance demand, and digital clinical trial services. As a result, the stock reflects a discount to this narrative."
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all
How Could You Get There Earlier?
This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.
- Company 1 - 28% below our estimate - builds out digital banking, insurance and payments to pull in underbanked customers.
- Company 2 - 27% below our estimate - folds recent acquisitions into a broader deposit base to support lending and fee income.
- Company 3 - 21% below our estimate - turns a copper cable niche into a full connectivity stack spanning optics and silicon.
Those are three of them. See the full list of 34 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com